financetom
Business
financetom
/
Business
/
JetBlue still in talks with multiple airlines for partnership
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JetBlue still in talks with multiple airlines for partnership
Feb 19, 2025 7:38 AM

NEW YORK (Reuters) - JetBlue Airways ( JBLU ) said on Wednesday that it is still in talks with multiple airlines to establish a partnership and is willing to allocate more funds to get a deal done.

In November, the Boston-based 1st U.S. Circuit Court of Appeals sided with the U.S. Department of Justice in blocking the JetBlue ( JBLU ) and American Airlines' ( AAL ) "Northeast Alliance," which had allowed the two carriers to coordinate flights and pool revenue.

"When I look at the benefits that we got from the partnership we had, I think that's something that's attractive for us," JetBlue ( JBLU ) President Martin St. George told the audience at the Barclays 42nd Annual Industrial Select Conference in Miami, Florida.

The biggest benefit of a partnership would be improving the utility of the company's loyalty points for customers which trails multiple competitors, he said.

"If we find a deal that's accretive, we'll absolutely do it," St. George said, adding that the company is looking forward to letting the Northeast Alliance "play out in the original design."

The Justice Department under the Biden Administration argued that the alliance would hurt consumers, saying the partnership eliminated incentives for American to cut prices to lure customers from JetBlue ( JBLU ), a historically disruptive rival with often lower fares.

St. George said there is money in its JetForward plan allocated for partnership but said if the number had to change, the company will provide a guide, adding that a financier would be good for the airline.

The company said its JetForward initiatives included priorities to improve the company's reliability, network, product and financial future, targeting $800 million to $900 million for incremental EBIT through 2027.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
May 20, 2024
(Reuters) - French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence. Sanofi said in a statement that the partnership with OpenAi will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will...
Nvidia earnings could spark $200 billion swing in shares, options show
Nvidia earnings could spark $200 billion swing in shares, options show
May 20, 2024
NEW YORK (Reuters) - Traders are pricing in a big move for Nvidia's ( NVDA ) shares after the chipmaker reports earnings on Wednesday, though expectations for volatility are more muted than in the past, U.S. options markets show. Nvidia's ( NVDA ) options are primed for an 8.7% swing in either direction by Friday, according to data from options...
Britain proposes obligations on Mastercard and Visa to increase competition
Britain proposes obligations on Mastercard and Visa to increase competition
May 20, 2024
LONDON, May 21 (Reuters) - There is no effective competition in core credit card services where Visa and Mastercard ( MA ) are the biggest players, and more transparency for users is needed, Britain's Payment Systems Regulator said in an interim report on Tuesday. The PSR found that over the past five years, and after taking account of volume changes,...
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
May 20, 2024
May 21 (Reuters) - French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence. Sanofi said in a statement that the partnership with OpenAi will allow it to access proprietary data to develop AI models for its biopharma models, while Formation...
Copyright 2023-2026 - www.financetom.com All Rights Reserved